走向理解溶酶体贮积症的分子病理学并开发治疗方法的旅程。
A Journey towards Understanding the Molecular Pathology and Developing Therapies for Lysosomal Storage Disorders.
机构信息
Medical Faculty, Institute of Biochemistry, University of Giessen, Friedrichstrasse 24, 35392 Giessen, Germany.
出版信息
Cells. 2021 Dec 23;11(1):36. doi: 10.3390/cells11010036.
Abstract
Lysosomal storage disorders (LSDs) are rare, monogenic diseases characterized by aberrant lysosomes with storage material [...].
摘要
溶酶体贮积症（LSD）是一种罕见的单基因疾病，其特征为溶酶体异常，伴有储存物质[...]。
相似文献
1
A Journey towards Understanding the Molecular Pathology and Developing Therapies for Lysosomal Storage Disorders.走向理解溶酶体贮积症的分子病理学并开发治疗方法的旅程。
Cells. 2021 Dec 23;11(1):36. doi: 10.3390/cells11010036.
2
Gene therapy approaches for lysosomal storage disease: next-generation treatment.溶酶体贮积症的基因治疗方法：新一代治疗方法。
Hum Gene Ther. 2012 Aug;23(8):808-15. doi: 10.1089/hum.2012.140.
3
Lysosomal storage disorders - challenges, concepts and avenues for therapy: beyond rare diseases.溶酶体贮积症——挑战、概念与治疗途径：超越罕见疾病。
J Cell Sci. 2019 Jan 16;132(2):jcs221739. doi: 10.1242/jcs.221739.
4
Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.溶酶体贮积症的联合疗法：对一个简单问题的复杂解答。
Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1(Suppl 1):639-48.
5
New strategies for the treatment of lysosomal storage diseases (review).用于治疗溶酶体贮积症的新策略（综述）。
Int J Mol Med. 2013 Jan;31(1):11-20. doi: 10.3892/ijmm.2012.1187. Epub 2012 Nov 19.
6
Treatments for lysosomal storage disorders.溶酶体贮积症的治疗方法。
Biochem Soc Trans. 2010 Dec;38(6):1465-8. doi: 10.1042/BST0381465.
7
SnapShot: Lysosomal Storage Diseases.快照：溶酶体贮积症。
Cell. 2020 Feb 6;180(3):602-602.e1. doi: 10.1016/j.cell.2020.01.017.
8
Intrauterine enzyme replacement therapies for lysosomal storage disorders: Current developments and promising future prospects.子宫内酶替代疗法治疗溶酶体贮积症：当前的发展和有前途的未来前景。
Prenat Diagn. 2023 Dec;43(13):1638-1649. doi: 10.1002/pd.6460. Epub 2023 Nov 13.
9
Gene therapy for lysosomal storage disorders.用于溶酶体贮积症的基因治疗。
Expert Opin Biol Ther. 2003 Aug;3(5):789-801. doi: 10.1517/14712598.3.5.789.
10
Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications.用于贮积病的造血干细胞基因治疗：当前及新适应症
Mol Ther. 2017 May 3;25(5):1155-1162. doi: 10.1016/j.ymthe.2017.03.025. Epub 2017 Apr 4.
本文引用的文献
1
Fabry Cardiomyopathy: Current Practice and Future Directions.《法布里心肌病：现状与未来方向》。
Cells. 2021 Jun 17;10(6):1532. doi: 10.3390/cells10061532.
2
3
Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development.基因治疗溶酶体贮积症：正在进行的研究和临床开发。
Biomolecules. 2021 Apr 20;11(4):611. doi: 10.3390/biom11040611.
4
Increased Alveolar Heparan Sulphate and Reduced Pulmonary Surfactant Amount and Function in the Mucopolysaccharidosis IIIA Mouse.黏多糖贮积症 IIIA 型小鼠肺泡肝素硫酸含量增加和肺表面活性物质含量及功能降低。
Cells. 2021 Apr 8;10(4):849. doi: 10.3390/cells10040849.
5
The Uncovered Function of the -Encoded Protein.- 编码蛋白的未被发现的功能。
Cells. 2021 Mar 12;10(3):630. doi: 10.3390/cells10030630.
6
Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased H NMR-Linked Metabolomics Strategy.利用无偏 NMR 代谢组学策略快速鉴定 GM1 型 2 型神经节苷脂贮积症的新型生物标志物。
Cells. 2021 Mar 5;10(3):572. doi: 10.3390/cells10030572.
7
Potential Treatment of Lysosomal Storage Disease through Modulation of the Mitochondrial-Lysosomal Axis.通过调节线粒体-溶酶体轴治疗溶酶体贮积症的潜力。
Cells. 2021 Feb 17;10(2):420. doi: 10.3390/cells10020420.
8
Optimization of Enzyme Essays to Enhance Reliability of Activity Measurements in Leukocyte Lysates for the Diagnosis of Metachromatic Leukodystrophy and Gangliosidoses.优化酶分析以提高白细胞裂解物中活性测量的可靠性，用于诊断异染性脑白质营养不良和神经节苷脂病。
Cells. 2020 Nov 28;9(12):2553. doi: 10.3390/cells9122553.
9
Highlights on Genomics Applications for Lysosomal Storage Diseases.基因组学在溶酶体贮积症中的应用亮点
Cells. 2020 Aug 14;9(8):1902. doi: 10.3390/cells9081902.
10
Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.黏多糖贮积症 I 型：自然病史和分子病理学综述。
Cells. 2020 Aug 5;9(8):1838. doi: 10.3390/cells9081838.
Zotero 插件